16-year-old girl raped by youth while his sister filming it

News Network
February 26, 2018

Muzaffarnagar, Feb 26: A 16-year-old girl was allegedly raped by a 22-year-old man, whose sister made a video of the incident, police said today.

The incident took place yesterday in the Civil Lines area of Muzaffarnagar in Uttar Pradesh.

The girl has alleged that she was taken to a house by the man's sister and raped. The accused also threatened her of dire consequences if she reported the matter, police said.

The police have registered a case on the complaint of the girl.

Comments

kumar
 - 
Monday, 26 Feb 2018

Ache din for rapists in India.

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 24,2020

Thane, Apr 24: A 34-year-old man was allegedly attacked on suspicion of being a COVID-19 patient and died after falling into a gutter during the assault in Kalyan town of Maharashtra's Thane district, police said on Friday.

The incident took place on Wednesday morning, when Ganesh Gupta had stepped out of his home to purchase some essentials amid the COVID-19 lockdown, an official said.

On noticing some policemen manning the street, the victim took an alternate route, where a few passersby assaulted him after he coughed while walking, he said.

The men suspected him of being a COVID-19 patient and attacked him, causing him to fall into a gutter and die, the official said.

The deceased's body was sent for post-mortem and a case of accidental death has been registered as of now, the station house officer of the Khadakpada police station said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 29,2020

Khammam, Jun 29: In an outrageous incident, some youths beat up a monkey and strung it up on a tree to death while also releasing dogs to attack it in Ammapalem village in Telangana's Khammam district.

A video of the heinous incident of animal cruelty has surfaced on social media, in which the monkey is seen hanging by a rope from a tree, desperately flailing its limbs while a couple of dogs attempt to pounce on and torment the hapless simian. After a while, several men are seen in the video approaching the animal with long sticks.

Forest officials have charged one villager Venkateshwar Rao under Wildlife Protection Act along with the other accused and arrested them. They were released on bail on Saturday and are set to be summoned for questioning by forest officials.

Rao had spotted the monkey, which had entered his residence apparently in search of food and beat it with a stick and hung it from a tree with the help of his friend.

In the video of the incident, Rao could also be seen instructing his pet dogs to bite the monkey, which was fighting for its life.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.